| 纯度 | > 95 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | AIMP3 |
| Uniprot No | O43324 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-174aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMAAAAELSLLEKSLGLSKGNKYSAQGERQI PVLQTNNGPSLTGLTTIAAHLVKQANKEYLLGSTAEEKAIVQQWLEYRVT QVDGHSSKNDIHTLLKDLNSYLEDKVYLTGYNFTLADILLYYGLHRFIVD LTVQEKEKYLNVSRWFCHIQHYPGIRQHLSSVVFIKNRLYTNSH |
| 预测分子量 | 22 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AIMP3重组蛋白的3篇参考文献示例(内容基于公开研究整理，非真实文献)：
1. **文献名称**：*AIMP3/p18 Requires Translocating to Nucleus for Its DNA Repair Function*
**作者**：Kim S, et al.
**摘要**：研究揭示了重组AIMP3蛋白通过核转位参与DNA损伤修复的机制，证实其与ATM激酶相互作用，调控细胞周期检查点及凋亡信号通路。
2. **文献名称**：*Recombinant AIMP3 Suppresses Tumor Growth by Modulating p53 Stability*
**作者**：Park JH, et al.
**摘要**：通过体外表达重组AIMP3蛋白，证明其通过抑制MDM2介导的p53泛素化降解，增强p53的稳定性，从而抑制肿瘤细胞的增殖和转移。
3. **文献名称**：*Structural Insights into the Tumor-Suppressive Role of AIMP3*
**作者**：Lee Y, et al.
**摘要**：利用重组AIMP3蛋白进行晶体结构解析，发现其N端结构域与tRNA合成酶复合物解离后，可独立激活下游抑癌信号通路，为靶向治疗提供依据。
如需具体文献，建议在PubMed或Web of Science中检索关键词“AIMP3 recombinant protein”或“AIMP3 function”。
AIMP3 (ARS-interacting multifunctional protein 3), also known as EMAPII or SCYE1. is a pleiotropic cytokine and a component of the multi-tRNA synthetase complex (MSC), a macromolecular assembly involved in protein synthesis and non-canonical regulatory functions. It is encoded by the *AIMP3* gene and plays critical roles in transcriptional regulation, cell proliferation, and apoptosis. Structurally, AIMP3 contains conserved domains that facilitate interactions with other MSC components, such as aminoacyl-tRNA synthetases, while its C-terminal region mediates extracellular signaling as a secreted cytokine.
Recombinant AIMP3 protein is produced using expression systems like *E. coli* or mammalian cells, followed by purification via affinity chromatography (e.g., His-tag). The recombinant form retains biological activity, including binding to cell surface receptors (e.g., CCRL1) to trigger pro-inflammatory responses or induce apoptosis in specific cell types. Notably, AIMP3 regulates tumor suppression by stabilizing p53 through direct interaction, enhancing p53-dependent pathways to inhibit uncontrolled cell growth. It also suppresses telomerase activity, contributing to cellular senescence and cancer cell death.
Research on recombinant AIMP3 has highlighted its dual role: intracellularly as a tumor suppressor and extracellularly as an immune modulator. Dysregulation of AIMP3 is linked to cancers, neurodegenerative diseases, and autoimmune disorders. Its therapeutic potential is being explored in oncology (e.g., targeting p53-deficient tumors) and immunotherapy. However, its pro-inflammatory properties require careful evaluation in clinical contexts. Current studies focus on elucidating its signaling networks and optimizing recombinant forms for biomedical applications.
×
